Liu S M, Tang T Q
Dept. of Internal Medicine, Affiliated Hospital, Jinan University Medical College, Guangzhou.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 1994 Aug;14(8):469-73.
40 Patients with chronic cor pulmonale (CCP) were treated with Feiyaning (FYN), a Yiqi Huoxue compound prescription, and ligustrazine (LT) were reported. The results showed that FYN and LT could lower the pulmonary artery pressure (PAP) significantly; decrease the pulmonary vascular resistance (PVR) as well as the consumption of oxygen in cardiac muscle; increase cardiac output (CO); improve some indices in hemorrheology; while PaO2 and SaO2 didn't change apparently. Moreover, lowering of FYN on PAP and PVR were superior to that of LT. The experimental studies showed that LT and injection of FYN could completely inhibit the hypoxia caused increase of PAP and PVR in rats; reduce the hypoxia caused pulmonary artery hypertension (PAH) and improve PVR of rats, as well as increase CO. The effects of FYN were superior to LT's. Although LT and FYN could decrease systemic arterial pressure to certain extent, they didn't induce systemic artery hypotension. It suggest that LT could reduce PAH definitely.
据报道，40例慢性肺源性心脏病（CCP）患者接受了益气活血复方制剂肺宁（FYN）和川芎嗪（LT）治疗。结果显示，FYN和LT均可显著降低肺动脉压（PAP）；降低肺血管阻力（PVR）以及心肌耗氧量；增加心输出量（CO）；改善血液流变学的一些指标；而动脉血氧分压（PaO2）和动脉血氧饱和度（SaO2）无明显变化。此外，FYN降低PAP和PVR的作用优于LT。实验研究表明，LT和肺宁注射液可完全抑制低氧引起的大鼠PAP和PVR升高；降低低氧所致的肺动脉高压（PAH），改善大鼠PVR，并增加CO。肺宁的作用优于LT。虽然LT和肺宁可在一定程度上降低体动脉压，但未引起体动脉低血压。这表明LT可确切降低PAH。
